Table 1.
Patient demographics, diagnosis, medical therapy, and median CRP at the time of referral for urgent access to care.
| Characteristics | Combined population n = 158 (100%) |
|---|---|
| Population characteristics | |
| Median age (years, [Q1–Q3]) | 37 [26–49] |
| Female (n, %) | 89 (56) |
| Smoking status (n, %) | |
| Current smoker | 18 (11) |
| Nonsmoker | 140 (89) |
| Crohn’s disease (n, %) | 123 (78) |
| Ulcerative colitis (n, % of total) | 18 (11) |
| Symptoms without diagnosis (n, % of total) | 17 (11) |
| New IBD diagnosis | 4 (31) |
| Medications at assessment (n, % of total) | |
| No therapy | 53 (34) |
| Monotherapy | 71 (45) |
| Corticosteroid | 4 (3) |
| 5-ASA | 12 (8) |
| Immunomodulator (IM)a | 8 (5) |
| Anti-TNFb | 29 (18) |
| Ustekinumab | 9 (5) |
| Vedolizumab | 7 (4) |
| Tofacitinib | 0 (0) |
| Clinical trial medicationc | 1 (1) |
| Rectal therapy only | 1 (1) |
| Multiple therapies | 34 (22) |
| Biologic + IM | 23 (14) |
| Corticosteroid + biologic/IM | 6 (4) |
| Corticosteroid + 5-ASA | 2 (1) |
| 1 (1) | |
| 5-ASA + IM | 2 (1) |
| Median CRP (in mg/L) | |
| Total [Q1–Q3] | 5.1 [1.8–13.0] |
| Crohn’s disease [Q1–Q3] | 4.3 [1.7–12.2] |
| Ulcerative colitis [Q1–Q3] | 8.0 [3.9–13.5] |
| 42 (27) | |
aImmunomodulators include thiopurine or methotrexate.
bIncludes biosimilar CPT-13, originator infliximab, adalimumab, golimumab.
cClinical trial drugs included rizankizumab and upacitanib.
Abbreviations: CRP = C-reactive protein; IM = immunomodulator; TNF = tumor necrosis factor.